About Novogen Limited (NASDAQ:NVGN)
Novogen Limited (Novogen) is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. Novogen has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate. It focuses on various cancers, including melanoma and prostate cancer.
Industry, Sector and Symbol:
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Sector: Biotechnology & Medical Research - NEC
- Symbol: NASDAQ:NVGN
- CUSIP: N/A
- Web: www.novogen.com
- Current Ratio: 3.62%
- Quick Ratio: 3.62%
Sales & Book Value:
- Annual Sales: $180,000.00
- Price / Sales: 83.99
- Book Value: $3.95 per share
- Price / Book: 0.79
- Outstanding Shares: 4,830,000
Frequently Asked Questions for Novogen Limited (NASDAQ:NVGN)
What is Novogen Limited's stock symbol?
Novogen Limited trades on the NASDAQ under the ticker symbol "NVGN."
Where is Novogen Limited's stock going? Where will Novogen Limited's stock price be in 2017?
1 brokers have issued 1 year price targets for Novogen Limited's stock. Their forecasts range from $5.00 to $5.00. On average, they anticipate Novogen Limited's stock price to reach $5.00 in the next year. View Analyst Ratings for Novogen Limited.
Who are some of Novogen Limited's key competitors?
Some companies that are related to Novogen Limited include Prana Biotechnology Ltd (PRAN), Cleveland BioLabs (CBLI), Fibrocell Science (FCSC), Oxford Pharmascience Group Plc (OXP), OncoGenex Pharmaceuticals (ACHV), Synairgen plc (SNG), Repros Therapeutics (RPRX), RXi Pharmaceuticals Corporation (RXII), Jaguar Animal Health (JAGX), Ixico Plc (IXI), Metabolix (YTEN), Roka Bioscience (ROKA), Akers Biosciences (AKR), Rosetta Genomics (ROSG), Celator Pharmaceuticals (CPXX), Cyprotex plc (CRX), Durata Therapeutics (DRTX) and GenVec (GNVC).
Who are Novogen Limited's key executives?
Novogen Limited's management team includes the folowing people:
- James B. Garner, Chief Executive Officer, Executive Director (Age 43)
- Gordon Hirsch, Chief Medical Officer
- Lilischkis Kimberley, Clinical & Regulatory Affairs Manager
- Peng K. Leong, Chief Business Officer
- Stephen Palmer, Program Director - Degenerative Diseases
- Justine R. Stehn Ph.D., Director - ATM Program
- Kate Hill, Interim Company Secretary
- Iain Ross, Non-Executive Chairman of the Board
- Bryce Carmine, Non-Executive Deputy Chairman of the Board
- Steven Roy Stent Coffey, Non-Executive Director
How do I buy Novogen Limited stock?
Shares of Novogen Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novogen Limited's stock price today?
One share of Novogen Limited stock can currently be purchased for approximately $3.13.
How big of a company is Novogen Limited?
Novogen Limited has a market capitalization of $13.91 million and generates $180,000.00 in revenue each year. The biotechnology company earns ($8,040,000.00) in net income (profit) each year or ($3.82) on an earnings per share basis.
How can I contact Novogen Limited?
Novogen Limited's mailing address is L 5 20 George St, SYDNEY, NSW 2077, Australia. The biotechnology company can be reached via phone at +61-2-94724101 or via email at [email protected]
MarketBeat Community Rating for Novogen Limited (NASDAQ NVGN)MarketBeat's community ratings are surveys of what our community members think about Novogen Limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Novogen Limited (NASDAQ:NVGN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$5.00 (59.74% upside)|
Consensus Price Target History for Novogen Limited (NASDAQ:NVGN)
Analysts' Ratings History for Novogen Limited (NASDAQ:NVGN)
(Data available from 11/18/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|2/28/2017||HC Wainwright||Set Price Target||Buy||$5.00||N/A|
Earnings History for Novogen Limited (NASDAQ:NVGN)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Novogen Limited (NASDAQ:NVGN)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Novogen Limited (NASDAQ:NVGN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Novogen Limited (NASDAQ NVGN)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Novogen Limited (NASDAQ:NVGN)
Latest Headlines for Novogen Limited (NASDAQ NVGN)
Novogen Limited (NASDAQ NVGN) Chart for Saturday, November, 18, 2017